Arcus Biosciences Inc. Common Stock (RCUS)
Stock · NYSE · Health Care
$22.14as of 10/16/2026
Price chart
Active signals
RCUS Signal Track Record
How signals performed across all stocks →What RCUS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | +3.6% | 59% | September 10, 2026 |
| Bollinger Band Breakout | 27 | -3.7% | 41% | August 25, 2026 |
| Bollinger Band BreakdownActive now | 18 | +3.4% | 67% | September 10, 2026 |
| 200-Day Moving Average TouchActive now | 16 | -5.9% | 31% | September 25, 2026 |
| Any 20-session window (baseline) | +0.9% | 52% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About RCUS
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 601
- Website
- arcusbio.com/
Fundamentals
- 1-day range
- $21.6$22.96
- Market cap
- $3.56B
- P/E (trailing)
- —
- P/E (forward)
- -6.99
- EPS (trailing)
- $-3.90
- Dividend yield
- —
- Beta
- 1.04
- Avg. volume
- 1.36M
How Arcus Biosciences Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 25, 2026 · via SEC EDGAR / Finnhub
Forecasts
12 analyst ratings
Arcus Biosciences Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- RCUSArcus Biosciences Inc. Common Stock$22.12▼ 3.07%Market cap $3.56BP/E —$15.38$31.74
- LEGNLegend Biotech Corporation American Depositary Shares$18.48▼ 6.67%Market cap $3.58BP/E —$16.24$37.5
- ALMSAlumis Inc. Common Stock$6.12▼ 3.01%Market cap $3.54BP/E —$4.37$31.35
- TLXTelix Pharmaceuticals Limited American Depositary Shares$10.69▲ 1.14%Market cap $3.60BP/E —$6.28$13.11
- IDYAIDEAYA Biosciences Inc. Common Stock$32.85▼ 2.95%Market cap $3.50BP/E —$26.44$42.68
- ELVNEnliven Therapeutics Inc. Common Stock$37.32▼ 5.11%Market cap $3.67BP/E —$14.79$62.32
- GPCRStructure Therapeutics Inc. American Depositary Shares$21.08▼ 5.00%Market cap $3.74BP/E —$25.59$94.9
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| RCUS Arcus Biosciences Inc. Common Stock | $3.56B | — | $22.12 | ▼ 3.07% | $15.38$31.74 |
| LEGN Legend Biotech Corporation American Depositary Shares | $3.58B | — | $18.48 | ▼ 6.67% | $16.24$37.5 |
| ALMS Alumis Inc. Common Stock | $3.54B | — | $6.12 | ▼ 3.01% | $4.37$31.35 |
| TLX Telix Pharmaceuticals Limited American Depositary Shares | $3.60B | — | $10.69 | ▲ 1.14% | $6.28$13.11 |
| IDYA IDEAYA Biosciences Inc. Common Stock | $3.50B | — | $32.85 | ▼ 2.95% | $26.44$42.68 |
| ELVN Enliven Therapeutics Inc. Common Stock | $3.67B | — | $37.32 | ▼ 5.11% | $14.79$62.32 |
| GPCR Structure Therapeutics Inc. American Depositary Shares | $3.74B | — | $21.08 | ▼ 5.00% | $25.59$94.9 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- William Blair Initiates Coverage On Arcus Biosciences with Outperform Ratingbenzinga · 10/16/2026
- Arcus Biosciences Announces New Employment Inducement GrantsYahoo · 10/9/2026
- Is Arcus Biosciences (RCUS) Undervalued As New Casdatifan Data Takes Center Stage?Yahoo · 10/6/2026
- How Investors Are Reacting To Arcus Biosciences (RCUS) Expansive New Casdatifan ARC-20 Kidney Cancer DataYahoo · 10/5/2026
- Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $43 Price TargetBenzinga · 9/30/2026
- Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of TherapyYahoo · 9/22/2026
- TD Cowen Initiates Coverage On Arcus Biosciences with Buy RatingBenzinga · 9/16/2026
- Arcus Biosciences, Inc. (RCUS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/15/2026
- 12 Health Care Stocks Moving In Monday's Pre-Market SessionBenzinga · 9/14/2026
Insider Activity
Insider Actions →- Azoy Alexander · August 21, 2026 · Option Exercise2.8K @ $15.44
- Azoy Alexander · August 21, 2026 · Sale2.8K @ $30
- Jaen Juan C. · July 10, 2026 · Sale268 @ $29.4
- Jaen Juan C. · July 10, 2026 · Sale19.8K @ $28.61
- Jaen Juan C. · July 9, 2026 · Sale48.5K @ $30.05
- Jaen Juan C. · June 24, 2026 · Sale6.4K @ $29.66
- Jaen Juan C. · June 23, 2026 · Sale1.7K @ $28.06
- Jaen Juan C. · June 23, 2026 · Sale14.1K @ $27.69
- Jaen Juan C. · June 22, 2026 · Sale9.2K @ $27.03
- Tang Carolyn C. · June 11, 2026 · Option Exercise34.1K @ $2.57
- Ribas Antoni · June 11, 2026 · Grant16.9K
- Ribas Antoni · June 11, 2026 · Grant5.7K
- Lambert Nicole · June 11, 2026 · Grant16.9K
- Lambert Nicole · June 11, 2026 · Grant5.7K
- Lacey David L. · June 11, 2026 · Grant16.9K
Institutional Ownership
March 31, 2026
- Total shares held
- 114.53M
- Total value held
- $2.46B
- Institutional holders
- 204
- Unknown31.42M
- Unknown15.23M
- Unknown6.09M
- Unknown5.41M
- Unknown5.03M
- Unknown3.86M
- Unknown3.78M
- Unknown3.76M
- Unknown3.01M
- Unknown2.25M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Arcus Biosciences gets JP Morgan coverage, adds grant program
JP Morgan started coverage of Arcus Biosciences with an Overweight rating and set a price target of $41. The firm’s initiation follows recent announcements that the company will provide new employment inducement grants to its staff. The coverage adds to an average analyst target of $40 and comes as the stock trades near the lower end of its 52‑week range. These developments may influence market perception of the company.
Arcus Biosciences gets JP Morgan coverage, adds grant program. JP Morgan started coverage of Arcus Biosciences with an Overweight rating and set a price target of $41. The firm’s initiation follows recent announcements that the company will provide new employment inducement grants to its staff. The coverage adds to an average analyst target of $40 and comes as the stock trades near the lower end of its 52‑week range. These developments may influence market perception of the company.